Clinical Trials
46
Active:0
Completed:43
Trial Phases
5 Phases
Phase 1:16
Phase 2:2
Phase 3:9
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials
Phase 1
16 (41.0%)Phase 4
10 (25.6%)Phase 3
9 (23.1%)Not Applicable
2 (5.1%)Phase 2
2 (5.1%)Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06889350
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06339788
- Locations
- 🇰🇷
Central Hospital, Siheung-si, Gyeonggi-do, Korea, Republic of
Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05688085
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05688098
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05663073
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found